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Highlights 
 Improvements in childhood cancer survival led to increasing numbers of survivors
 Childhood cancer is treated within multiinstitutional clinical trials
 Chemotherapy is the main element of therapy but irradiation is still needed in some
 Survivors are at longstanding risk of severe somatic late effects
 Survivors may face various social and socioeconomic difficulties in adulthood
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Abstract 
Since the 1960s, paediatric oncologists have gradually become better organised in large study 
groups and participation in clinical trials is today considered as the standard of care, with most 
children with cancer in Europe and North America being enrolled on available treatment 
protocols. Chemotherapy is nowadays the main element of therapy, but irradiation is still 
required for some patients. With the advent of multimodality therapy and supportive care, five-
year cancer survival exceeds 80% in most European and North American countries today. The 
substantial improvements in survival led to a constantly growing population of childhood 
cancer survivors. Concerns regarding the risk of late effects of the intensive cancer treatment at 
a young age, together with increasing numbers of survivors, have directed attention towards 
survivorship research. Survivors of childhood cancer are at longstanding risk of various severe 
somatic and mental health conditions attributable to the cancer and its treatment, as well as 
adverse social and socioeconomic consequences, and diminished psychological well-being and 
quality of life. It is, however, important to stress that some survivors have no or very mild 
adverse health conditions. Nevertheless, joint efforts are warranted for the care and long-term 
follow-up of childhood cancer patients. 
With this article, we provide a comprehensive overview of improvements in survival and 
treatment modalities over time, as well as the related somatic and mental late effects, and social 
and socioeconomic difficulties that these children might encounter later in life. 
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Introduction 
Childhood cancer is a heterogeneous group of malignancies, consisting of a range of very 
different diseases with different patterns of occurrence (1), aetiology (2), treatment and 
supportive care, survival (3) and the risk of acute toxic side and late effects (4, 5). Over the past 
five decades, substantial advances in diagnostics, pharmacology, treatment combinations and 
techniques have led to large improvements in survival from childhood cancer and declining 
mortality rates (6, 7). Overall survival of childhood cancer has improved from 30% in the 1960s 
to now exceeding 80% in most high-income countries (3). However, not all children benefit 
equally from these improvements and outcome depends upon type of malignancy, age of 
clinical onset, anatomical site, stage of the disease (in solid tumor) and somatic genetic lesions. 
Further, survival varies substantially by region of the world, as well as within regions (3, 8, 9). 
The latter applies especially to resource-limited settings, and to a much lesser extent - but still 
measurable - to high-income countries by social and socioeconomic group (10). 
Because of improving survival and lack of preventive measures to preclude the disease (2, 11), 
the number of childhood cancer survivors reaching adulthood is steadily increasing. This 
growing population, with many years of life ahead of them, has increased attention and concerns 
about the risk of late effects induced by cancer treatment exposures at a young age (12) and 
attracted great interest towards survivorship research (13-15). Survivors of childhood cancer 
are at risk for various somatic and mental health conditions attributable to the cancer and its 
treatment (4, 5) as well as adverse social and socioeconomic consequences and diminished 
psychological well-being and quality of life (16-19). 
In this article, we provide a comprehensive overview of the developments and improvements 
in childhood cancer survival and treatment modalities over time, summarize the wide range of 
somatic and mental late effects as well as the social and socioeconomic difficulties that 
childhood cancer survivors may encounter later in life and highlight the need of long-term 
follow-up care to facilitate early detection of health problems and social support. 
Survival from childhood cancer 
Before 1960, childhood leukaemia, the most common type of childhood cancer, was considered 
a deadly, mostly incurable disease (20). Currently, 5-year population-based survival of 
childhood acute lymphoblastic leukaemia (ALL) exceeds 90% in some European and North 
American countries (8, 9). 
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For all childhood cancers combined, 5-year survival in Europe increased from 54% in 1978-
1982 to 75% in 1993-1997 (21), and approached 80% in 2005-2007 (3). In the US, 5-year 
relative survival rose from 58% in 1975-1977 to 85.3% in 2009-2015 (22). Survival has, 
however, not increased similarly in all parts of the world: reliable population-based cancer 
registry data are limited or entirely lacking in many low and middle-income countries (23), but 
estimates suggest that survival is substantially lower compared to high-income settings (8). A 
simulation study estimated that 5-year survival for all childhood cancers combined was only 
8.1% in Eastern Africa in 2015 (95% uncertainty interval 4.4-13.7%) (24). Further, it was 
estimated that in 2017, childhood cancers (0-19 years) were responsible for over 11 million 
years of life lost globally, with an overwhelming majority (61%) being observed in low- and 
low-middle income settings (25). 
Irrespectively of the country’s wealth and health expenditure, survival varies widely by 
childhood cancer type. Despite evidence suggesting that recent survival improvements were 
larger for acute myeloid leukaemia (AML) than for ALL in many countries (9), survival from 
ALL is still consistently higher than that for AML in Europe (3), the US (26), Japan (27), 
Australia (28), and globally (9, 24). Five-year survival exceeds 70% for AML in some high-
income countries, exceeds 90% for Burkitt and Hodgkin lymphoma, retinoblastoma, and 
nephroblastoma, but it is still below 60% for some types of hepatic and central nervous system 
(CNS) tumours (3, 9, 24, 26). Large survival disparities across regions of the world are also 
observed for individual childhood cancer types (3, 8). Figure 1 illustrates the international 
disparities in survival from ALL and from brain tumours, based on population-based survival 
estimates from the international CONCORD-3 programme (8). 
Important prognostic factors for childhood cancers can include sex and age at diagnosis as well 
as disease subtype, site, histology, grade, stage, and other clinical factors (29-34). Infants (<1 
year) and older children (>10 years) have the poorest prognosis for all cancers (3, 9, 35) except 
for some embryonal tumours, for which infants have a better prognosis than older children (3, 
36-38). Evidence is accumulating that not only clinical factors, but also factors indicating low
socioeconomic status, are associated with worse survival even within European countries (10, 
39-46), where mostly equal access to health care services, irrespective of socioeconomic
background, is presumed. Cancer survival for children has also been reported to vary by race 
or ethnicity, mainly based on data from the US (36, 47-50). Noteably a recent mediation 
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analysis found that the racial or ethnic survival disparities for childhood cancer in the US were 
only partly explained by socioeconomic differences (51). 
Treatment of children with cancer over time 
Chemotherapy was introduced as a treatment for childhood leukaemia in the 1950s, but still all 
patients died. In an attempt to change this, a number of clinical trials introduced protocol-based 
combination of chemotherapy despite resistance from academia (52), and paediatric acute 
lymphoblastic leukaemia became the first example of cure of disseminated cancer. Since the 
1960s, paediatric oncologists have organised to form large multidisciplinary study groups, and 
participation in clinical trials is today considered as the standard of care with most children in 
Europe and North America being enrolled on available protocols (53), ultimately contributing 
to substantial improvements in survival. The hallmark of the success of leukaemia therapy was 
the acceptance of proposals to categorize leukaemia by cell subtypes and morphological 
subgroups and to design treatment protocols accordingly. 
The success of leukaemia therapy has paralleled advances in diagnostics for subgrouping, 
targeted therapy and risk classification. The in vivo response to therapy evaluated by measurable 
residual disease has emerged as the most important prognostic factor in leukaemia, and is used 
for treatment stratification in most clinical trials (34). The genetic-based characterisation of 
tumours has led to significant changes in classification e.g. in medulloblastoma, which was 
previously characterised as one homogenous malignancy, but is currently subdivided into four 
main groups on the basis of differences in genetic alterations, age at onset and prognosis, 
thereby also emphasising sub-group-tailored therapy (54). 
Treatment of solid tumours has progressed from being a solely surgical approach with low 
survival probabilities, to the addition of radiation and later replacement by a multi-modality 
treatment mainly based on chemotherapy, which has resulted in significant improvements in 
survival. As the late effects of irradiation became evident, the number of patients receiving 
irradiation has been successfully reduced, e.g. in Wilms tumour patients and very young 
children with brain tumours, while irradiation is still essential in many other solid tumours (55). 
However, regional differences do exist with irradiation being used more often in North America 
compared to Europe (56). Importantly, newer approaches for delivery of radiation therapy, 
including conformal radiation, intensity modulated radiotherapy and proton therapy, have been 
introduced with the intent to reduce the adverse long-term effects of radiation (57). CNS 




irradiation was given to most children with leukaemia in the 1970s but has gradually been 
replaced by chemotherapy. This change in treatment modalities has resulted in a significant 
decline of irradiation-induced late effects, although the overall burden of late effects remains 
relatively high (58, 59) (please see section somatic and mental late effects). 
 
Modern therapy for some malignancies is very intensive and while survival has gradually 
improved, so has the risk of treatment-related death. There is a delicate balance between 
efficacy and toxicity, and it is considered that the upper limit of treatment intensity has been 
reached in many diseases (60). The aim of many current protocols is to identify patients, for 
whom therapy intensity can be reduced, and thereby the physical burden of treatment, without 
jeopardising survival. Thus, it is evident that collaboration on an international level is necessary 
to continue to build upon the major improvements already achieved in the management of 
childhood cancers. 
 
There is a large inter-individual variation in the pharmacokinetic of cytostatic drugs. A few 
constitutional risk factors for specific toxicities are known, e.g. TPMT status during 6-
mercaptopurine therapy, anthracycline-induced cardiotoxicity (61), or mitochondrial mutations 
leading to a high risk of deafness when exposed to aminoglycoside (62). Further studies of 
single nucleotide polymorphism variants increasing the susceptibility to acute and/or long-term 
toxicities of cancer drugs may ultimately lead to personalised precision medicine approaches 
for the treatment of childhood cancers. 
 
A substantial and not quantifiable proportion of patients in resource-poor countries have limited 
access to diagnostics and therapy, and may not receive any therapy for economic or cultural 
reasons (63). If treatment is initiated, blood support as well as management of infections and 
nutritional problems may be a hurdle in most low-income countries. The early mortality rate 
has been reported to be extremely high in low-income countries compared to high-income 
countries (7, 64). 
 
Somatic and mental late effects  
Over the past decades, it has become increasingly evident that survivors of childhood cancer 
may experience, to varying degrees, a wide range of adverse health outcomes resulting from 
previous therapeutic exposures that can affect almost any organ or body system (65). Several 
comprehensive cohorts of childhood cancer survivors have been established in Europe and 
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North America to assess the risk of a large variety of somatic and mental late effects. Table 1-
4 provide a summary of the largest and most comprehensive studies to date on somatic and 
mental late effects based on these childhood cancer survivor cohorts, as reported by the 
respective cohort investigators. Other cohorts are being established, such as the nationwide 
population-based French Childhood Cancer Observation Platform (CCOP) (66), which is based 
on the French national childhood cancer registry and includes detailed treatment information 
abstracted from medical records. 
In general, only few studies have been able to provide a comprehensive overview of the 
complex and often serious somatic disease burden after childhood cancer (59, 67-73) (Table 1). 
Large studies from North America and the Netherlands, with comprehensive clinical 
examination of various chronic health conditions, have provided evidence of a substantial 
somatic disease burden among childhood cancer survivors (58, 59, 67, 68). Bhakta et al. found 
that, by age 50 years, survivors had experienced on average 17 grade 1-5 chronic health 
conditions including five health conditions classified as grade 3-5 (severe/disabling, life-
threatening or fatal), as compared to on average nine grade 1-5 chronic health conditions in 
community controls (67). Additionally, large-scale population-based cohorts from the Nordic 
countries and Canada have assessed late effects using high quality registry-based data and 
provided novel evidence of consistently elevated risks of hospital contacts or visits to 
physicians for somatic diseases in a lifelong perspective (69-72). Among more than 21,000 5-
year childhood cancer survivors from the Nordic countries, survivors were found to be twice as 
likely to be hospitalised and experienced longer stays in hospitals than population-based 
comparisons (69). In the Canadian setting, McBride et al. reported an almost 2-fold higher 
utilisation of outpatient visits to physicians among survivors compared to the general 
population (72).  
Assessing temporal patterns in the risk of chronic health conditions (Table 1), Gibson et al. 
from the Childhood Cancer Survivor Study found that the 20-year cumulative incidence of such 
conditions decreased significantly over three decades from 33.2% in 1970-1079 to 27.5% in 
1990-1999. Such improvements were, however, not observed across all childhood cancer types 
(58). Based on a clinical assessment of long-term survivors of childhood ALL treated between 
1962 and 1991, Mulrooney et al. from the St. Jude Lifetime Cohort study demonstrated that 
despite significant changes in therapy over time, the overall cumulative burden of chronic health 
conditions in ALL survivors has remained high, whereas the pattern of morbidity has changed 
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substantially (59). It is, however, important to stress that many of the conditions driving the 
overall increased risk in ALL survivors were mild chronic conditions, such as growth hormone 
deficiency (24% vs 2% among controls) and neuropathy (e.g. peripheral sensory neuropathy: 
30% vs 13% among controls).  
Compared with cancer incidence in the general population, childhood cancer survivors also face 
an elevated risk of second malignant neoplasms (74-78) (Table 2). A Dutch study reported an 
overall 5-fold increased risk of second malignant neoplasms, equivalent to 20 excess cancers 
per 10,000 person-years (74). Three large studies with unique data deriving from the EU-funded 
PanCareSurFup consortium (www.pancaresurfup.eu) demonstrated a 22- and a 30-fold 
increased risk of subsequent primary bone cancer and soft-tissue sarcomas in five-year 
childhood cancer survivors, respectively (75, 77), and a four-fold increased risk of subsequent 
leukaemias (76) compared to population norms. 
Other studies have often focused on a single health outcome or organ system (79-89) (Table 3). 
Compared to the general population or siblings, some of these studies reported a 4.8-fold 
increased risk of hospital contact for any endocrine disorder (82), an 8.5-fold increased risk of 
stroke among irradiated survivors (81), a 6.8-fold increased risk of respiratory mortality (86), 
and more frequent hearing loss among survivors of childhood cancer (87). Increasingly, 
research has focused on the role of genetic susceptibility in determining risk of long-term 
adverse outcomes (90), including recently published findings from the large EU-funded 
PanCareLIFE consortium (www.pancarelife.eu), indicating an increased risk of cisplatin-
induced ototoxicity in carriers of specific genetic polymorphisms (ACYP2 rs1872328 variant 
and SLC22A2 rs316019) (88). 
Beyond the high risk for somatic late effects, experiences related to the childhood cancer 
diagnosis itself or potential consequences of the subsequent treatment may also adversely affect 
the mental health of survivors (18, 19, 91, 92) (Table 4). While studies from North America 
and Switzerland have reassuringly reported low or similar levels of psychological distress 
among survivors compared to the general population (18, 19), subgroups of survivors with poor 
physical health conditions experience elevated psychological distress, including symptoms of 
depression, anxiety, and psychotic tendencies (18, 19). Elevated levels of psychological distress 
may contribute to the observed increased use of various antidepressants (92) and higher rates 
of suicide ideation among survivors (91). Moreover, two population-based register studies from 




Denmark and Canada both provided evidence of greater risks of hospitalisations and mental 
health care visits for severe mental health disorders among childhood cancer survivors than in 
the general population (93, 94).  
 
Social and socioeconomic difficulties in childhood cancer survivors  
The immediate impact of a cancer diagnosis and its treatment during childhood may, apart from 
somatic and mental conditions, result in maladaptive coping, missed educational achievements, 
isolation or reduced interaction with peers, and social engagements (17, 95, 96). Moreover, 
experiencing a cancer during childhood, suffering from somatic or mental late effects or other 
adverse health conditions may also affect social and family life and diminish socioeconomic 
achievements during later life (16-19).  
 
The current literature indicates that childhood cancer survivors are at increased risk of several 
adverse socioeconomic and social conditions compared to individuals who did not suffer from 
cancer during childhood (16). Several large-scale studies observed lower educational 
attainments in childhood cancer survivors compared to cancer-free children (97-100), although 
findings from Switzerland suggested rather a delay in educational achievement than a long-
lasting difference (101). Empirical observations on the employment situation and occupation 
of childhood cancer survivors are less conclusive and varied by geographical region (16, 102). 
Findings from two systematic reviews and meta-analyses point towards a 1.5–2 times increased 
risk of unemployment in childhood cancer survivors (102, 103). Specifically, survivors in the 
US and Canada appear to be at greater risk of being unemployed (102), whereas observations 
from Europe were less consistent. Some studies found higher unemployment rates among 
European survivors compared to the general population (104-106), whereas others did not (100, 
107-110). Both a lower educational attainment and unemployment may have a direct impact on 
the survivors’ economical situation. Several studies found the survivors’ income to be markedly 
lower compared to their siblings or the general population (16, 100, 106, 111, 112). Empirical 
knowledge on the uptake of social security benefits such as benefits referring to unemployment, 
sickness, disability, rehabilitation or permanent invalidity is particularly sparse but does suggest 
an increased uptake of such benefits in childhood cancer survivors (16). In general, survivors 
of CNS tumours, survivors treated with cranial radiotherapy, and those diagnosed at younger 
age have a higher risk of adverse socioeconomic outcomes, irrespective of cancer type, although 
the underlying mechanisms are not well understood (16).  
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Overall, childhood cancer survivors tend to leave the parental home at an older age (113, 114) 
and have lower rates of marriage or cohabitation (115-118) than young adults without a cancer 
diagnosis during childhood. Findings from Denmark showed that CNS tumour survivors, and 
male survivors in particular, had a lower probability of leaving the parental home in early 
adulthood (113). Such patterns were, however, not seen in survivors of other diagnostic 
groups (113). Similar findings were found in a study from the US with survivors being more 
than twice as likely to stay at the parental home compared to a sibling comparison group, with 
survivors diagnosed with a CNS tumour or leukaemia having the greatest odds (119). Findings 
from Europe and North America (115-118) consistently revealed lower marriage and 
cohabitation rates among childhood cancer survivors compared with peers. A CNS tumour 
diagnosis, history of cranial irradiation, and male sex appeared to be the most important 
predictors of not having a partner (115, 116, 118). Despite the reduced rates of marriage and 
cohabitation, evidence does however not support that separation or divorce is more frequent 
in survivors than in the general population or in sibling comparisons (116, 118, 120). 
Observations on parenthood and infertility revealed that female and male childhood cancer 
survivors are less likely of ever parenting a child (117, 121-123). This may be a result of both 
biological repercussions of the childhood cancer including treatment-induced fertility 
problems, psychosocial consequences, difficulties in finding a partner, or concerns about the 
health of their future children. Impaired fertility may be caused by the oncological treatment 
such as radiation therapy in the pelvic area or certain chemotherapeutic drugs, especially 
alkylating agents, which can induce sperm alteration, ovarian failure or earlier menopause (124-
127). 
Perspectives 
With the advent of multimodality therapy, the survival from childhood cancer has markedly 
improved over the past five decades (3). Reports from the US and Europe, however, indicate 
that the relative increase in survival for several childhood cancer subtypes has decreased during 
recent years (3, 8).  
Over the last decades, in an effort to provide comparable population-based survival estimates 
to inform health policy-makers, health care professionals and scientists, a number of European 
(128-131) and international (8, 132-136) collaborations have been created, with only one being 
specifically dedicated to children with cancer (137). Survival is challenging to study due to 
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differences in cancer registration practices, in particular for CNS tumours with tumours of 
benign behavior and those without microscopic verification (8). Although stage at diagnosis is 
well known to influence survival, the collection of data on stage at diagnosis in population-
based cancer registries is very challenging. Until recently, if at all recorded, childhood cancer 
stage used to be coded according to the TNM classification for adults, due to lack of childhood-
specific guidelines (138). However, the recent development of guidelines for harmonising stage 
records in childhood cancer registries are an important step, and will enable analyses of survival 
according to stage in the years to come (138, 139). 
With the recognition that survivors of childhood cancer were at increased risk of long-term 
adverse outcomes, paediatric oncology professionals have continually worked toward the goal 
of maximising the chance of survival, while minimising long-term toxicities. Recent studies 
have provided convincing support that treatment modifications have resulted in overall 
improved long-term outcomes and lifespan extension for many survivors of childhood cancer, 
although not uniformly across all types of childhood cancer (58, 140). The lower increase in 
survival and improvements in long-term outcomes underscore the importance of further 
research addressing specific types of childhood cancer. 
As underlined more than 40 years ago by Dr Giulio J. D’Angio, most survivors need lifelong 
survivorship care (141). However, implementing follow-up care for childhood cancer has 
proven challenging across the globe (142). As risk-based survivorship care is complex, this 
might be one reason for many survivors not receiving optimal care. Another reason might be 
lack of harmonised evidence-based guidelines, which was met in 2010, when the International 
Late Effects of Childhood Cancer Guideline Harmonisation Group (IGHG; www.ighg.org) for 
long-term follow-up of children, adolescence, and young adult cancer survivors was initiated. 
This international initiative will largely contribute to standardise survivorship care across the 
globe and improve long-term outcomes in childhood cancer survivors in the years to come. 
Based on these international guidelines for surveillance of late effects, a new EU-funded 
collaborative project PanCareFollowUp (www.pancarefollowup.eu), with the overall aim of 
improving the quality of life for survivors of childhood and adolescent cancer by bringing 
together evidence-based, person-centered care to clinical practice, was initiated. Four state-of-
the-art clinics in Sweden, Belgium, Italy, Czech Republic are actively involving patients as 
partners to empower survivors and to support self-management. Experiences from 
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PanCareFollowUp and other international initiatives are urgently needed to further contribute 
to standardised and evidence-based survivorship care in other regions of the world and to 
ultimately improve outcomes after childhood cancer in a global context. 
Continued and concerted efforts are required from researchers, clinicians and policy-makers to 
address the need of survivors; i.e., effective innovative treatments, financial support aiming at 
reducing inequalities and increasing access to standard care, expertise and clinical research as 
well as tailored follow-up care throughout lifespan to facilitate early detection of health 
problems and social support. The overall aim is to improve the health and quality of life (143), 
and to ensure that ‘the increasing numbers of successfully treated children of today do not 
become the chronically ill adults of tomorrow’ (141). 
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Table 1: Summary of the largest and most comprehensive studies on somatic disease burden based on childhood cancer survivor cohorts in Europe and 

































≥18 years of age. 
5522 
survivors of 


































By age 50, survivors had experienced, on 
average 17.1 (95% CI 16.2-18.1) grade 1-5 
chronic health condition, of which 4.7 (4.6-
4.9) were grade 3-5. The cumulative burden in 
survivors was significantly greater than in 
community controls (p<0.0001). Cumulative 
burden of chronic health conditions at age 50 
years was highest in survivors of CNS 






















































By age 30, survivors had experienced, on 
average 5.4 chronic health conditions, 
including 3.2 graded as moderate, severe or 
life-threatening. Survivors had more growth 
hormone deficiency, hypogonadism, and 
neuropathy than controls. Elimination of 
cranial radiation from more recent treatment 
protocols was associated with a higher 
cumulative burden for musculosketetal and 
endocrine disorders. 
































































20 year cumulative incidence of at least one 
grade 3-5 condition decreased in more recent 
treatment eras (33.2% in 1970s to 27.5% in 
1990s), which was higher than for siblings 
(4.6%). Declines in cumulative incidence by 
treatment era were noted for endocrinopathies, 
subsequent malignant neoplasms, 






















































74.5% of survivors had at least one adverse 
event and 24.6% had five or more adverse 
events. 40% of survivors had one or more 
severe or life-threatening or disabling event. 
Highest or most severe burden of adverse 
events was observed most often among 
survivors receiving radiotherapy only (55%), 











































Survivors' risk of a first hospitalisation for any 
somatic disease (excluding cancer re-
occurrences) was 2-fold compared to the 
general population (RR: 1.95, 95% 1.91-1.97), 
yielding an AER of 3.07 (95% CI: 2.98-3.16) 
per 100,000 person-years. Most common 
reasons were diseases of the nervous system, 
endocrine system, digestive organs, and 
respiratory system. Survivors spent on average 
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before 21 years 
of age. 














































Leukaemia survivors were twice as likely to 
experience a first time hospital admission for a 
somatic disorder than the general population 
(RR. 2.08, 95% CI: 1.96-2.20), which 
remained increased beyond 20 years after 
leukaemia diagnosis. AER of leukaemia 
survivors was 32.4 per 1000 person-years 
(95% CI: 28.9-35-9). Survivors of CML had 
the largest absolute and relative risk of 























































Survivors were at higher risk of least one 
hospital-related morbidity than comparisons 
(41% vs. 17%, RR: 4.1, 95% CI: 3.7-4.5), with 
highest excess risk for neoplasm (including 
relapse or second cancer), blood disorders, and 
diseases of the nervous system. CNS tumour 
survivors were at highest excess risk of 
multiple morbidities. Morbidity was elevated 
for any combination of treatment, and highest 
for combination of radiation, chemotherapy 





















































During the 3-year follow-up period, 97% of 
survivors visited at least one physician, 
compared with 50% in the general population. 
Survivors were more likely to visit a general 
practitioner (excluding oncologists) at least 10 
times (RR: 2.23, 95% CI: 2.0-2.4) and were 
more likely to visit a specialist as an expected 
result of known late effects (RR: 2.57, 95% CI 









2.4 to 2.8). Survivors receiving combinations 
of treatment modalities utilised physicians and 


















the age of 18 
years and 














































The risk of at least one late effect was 5-fold 
increased (95% CI. 3.0-8.6) among 
transplanted survivors than non-transplanted 
survivors. Compared with French normative 
data, survivors reported lower HQoL scores on 
mental health, but no difference on physical 
health. 
AER; Absolute excess risk, ALL; Acute lymphoblastic leukaemia, AML; Acute myeloid leukaemia, CML; Chronic myeloid leukaemia, CTCAE; Common Terminology 
Criteria for Adverse Events, CNS; Central nervous system, GSI; Global severity index, HSCT; hematopoietic stem cell transplantation, HQoL; Health-related quality of life, 
 ICD; International classification of diseases, NCSI; National Cancer Survivorship Initiative, OR; Odds ratio, O/E; Observed/expected, RR; Risk ratio, SIR; Standardised 
incidence ratio, SMR; Standardised mortality ratio, SPN; Subsequent primary neoplasm 
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Table 2: Summary of the largest and most comprehensive studies on the risk of second malignant neoplasms based on childhood cancer survivor cohorts in 







































































dose, field and 
boost/surdosage 
for radiotherapy, 
and drug name, 
cumulative dose 







Survivors had an increased risk of any SMN 
compared with cancer incidence in the general 
population (SIR: 5.2, 95% CI: 4.6-5.8), with 
20.3 excess cancers per 10,000 person-years. 
Treatment with doxorubicin increased the risk 
of subsequent solid cancers and breast cancer, 
whereas treatment with cyclophosphamide 



































record). For ALL 
survivors treated 




















1-3 of clinical 
follow-up 
care. 
By 45 years from diagnosis, overall cumulative 
risk of any SPN, non-neoplastic death, or non-
fatal non-neoplastic condition among survivors 
of NCSI level 1, 2 or 3 were 21%, 45% and 
69%. For SPNs and non-neoplastic deaths, the 
excess risk also increased with increasing 
NCSI levels. 






































































Survivors had significantly higher risk of soft-
tissue sarcoma than expected (standardised 
incidence ratio (SIR): 29.9, 95% CI: 23.7-
37.2), with highest risk for malignant 
peripheral nerve sheath tumours, 
leiomyosarcomas and fibromatous neoplasms. 
AER for all soft-tissue sarcomas were low at 
all years from diagnosis (AER: <1 per 10,000 
person-years) except for leiomyosarcoma 
following retinoblastoma (AER: 52.7 (95% CI: 
20.0-85.5) per 10,000 person-years) among 
patients who had survived at least 45 years 

































































Survivors had a four-fold increased risk of 
subsequent primary leukaemia than expected 
(SIR: 3.7, 95% CI: 3.1-4.5) with AER of 7.5 
(95% CI: 6.0-9.2) per 100,000 person-years. 
The risk remained significantly elevated 
beyond 20 years from first primary cancer 
diagnosis (SIR: 2.4, 95% CI: 1.6-3.4). 















age 20 years in 



















































Survivors had a 22-fold increased risk of 
subsequent primary bone cancer than expected 
(SIR: 21.7, 95% CI: 19.0-24.6). Survivors had 
an AER of 2.0 (95% CI: 1.7-2.3) per 10,000 
person-years with greatest risk among 
survivors of retinoblastoma, bone sarcoma, and 
soft-tissue sarcoma. AER declined linearly 
with both years since diagnosis and attained 
age (all p<0.05). Beyond 40 years from 
diagnosis and beyond 40 years of attained age, 
the AER was at most 0.45 per 10,000 person-
years. 
AER; Absolute excess risk, ALL; Acute lymphoblastic leukaemia, AML; Acute myeloid leukaemia, CML; Chronic myeloid leukaemia, CTCAE; Common Terminology 
Criteria for Adverse Events, CNS; Central nervous system, GSI; Global severity index, HSCT; hematopoietic stem cell transplantation, HQoL; Health-related quality of life, 
 ICD; International classification of diseases, NCSI; National Cancer Survivorship Initiative, OR; Odds ratio, O/E; Observed/expected, RR; Risk ratio, SIR; Standardised 
incidence ratio, SMR; Standardised mortality ratio, SPN; Subsequent primary neoplasm 
*PanCareSurFup was an EU-funded consortium active from 2011-2017, but more publications are expected in the years to come. http://www.pancaresurfup.eu/ 
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Table 3: Summary of the largest and most comprehensive studies on single health outcome or organ-specific late effects based on childhood cancer survivor 














































before the age of 




disease within 5 
































































n or leading 
to death). 
Low, moderate and high-risk groups for 
cumulative incidence of heart failure among 
survivors at age 40 years were predicted to be 
0.5%, 2.4%, and 11.7%, respectively. In 
comparison, siblings had a cumulatice 
incidence of 0.3%. The relative risk of heart 
failure among survivors compared to siblings 
were only minimally increased for the low-risk 
group (p>0.05) but statistically significantly 
elevated for the moderate-risk and high-risk 
groups (p<0.01). When the CCSS results were 
compared with the external cohort of 












































Survivors had an overall 4.8-fold (95% CI: 
4.6-5.0) increased risk of hospital contact for 
any endocrine disorder, equivalent to AER of 
about 1000 per 100,000 person-years before 20 
years of age, and 400 per 100,000 person-years 
during the remaining lifetime. Survivors of 
leukaemia, CNS tumours and Hodgkin's 
lymphoma were at highest risk. Among the 
endocrine disorders investigated, pituitary 
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before 21 years 
of age. 
hypofunction predominated, representing 25% 











cohort of 5-year 
cancer survivors 
aged ≥16 years at 
survey and 
diagnosed in 




















c agent, thoracic 
surgery (yes/no), 
radiotherapy and 
doses to the 
thorax (no 
radiation, 1-19 
Gy, 20-39 Gy, 
≥40 Gy), and 
HSCT 
(autologous, 













After 35 years of follow-up, the cumulative 
incidence of any pulmonary disease was 21%. 
Survivors had an increased risk of pulmonary 
disease compared to siblings, especially 
pneumonia (p=0.020) and chest wall 
abnormalities (p=0.003). Risk factors for 
pneumonia were treatment with busulfan, 
whereas thoracic surgery was associated with 












cohort of 5-year 
cancer survivors 
diagnosed in 










































Survivors reported hearing loss more 
frequently than siblings (p<0.001), including 
unilateral and bilateral, and more severe 
hearing loss (25%). CNS tumour survivors 
were at highest risk. Tinnitus prevalence was 
similar for survivors and siblings. Treatment 
with platinum compounds (cisplatin, 
carboplatin, or both), high doses of cranial 
radiation, brain surgery, or bone marrow 
transplant increased the risk of hearing loss 
among survivors. Hearing loss prevalence 
declined in more recent treatment periods. 




































Survivors had a 6.8 times (95% CI: 5.8-7.9) 
higher risk of a respiratory death than expected 
in the general population, equivalent to 2.3 
(95% CI: 1.8-2.7) excess respiratory deaths. 
Highest excess risk was observed among CNS 
tumour survivors.  The number of excess 
respiratory deaths declined among survivors 




















all types of 





















All survivors treated with abdominal 
radiotherapy were at increased risk of 
gestational diabetes mellitus (RR: 3.35, 95% 
CI: 1.41-7.93) and anemia complicating 
pregnancy (RR: 2.10, 95% CI: 1.27-3.46) 
compared with survivors treated without 
radiotherapy. Survivors treated without 
radiotherapy had similar risks of pregnancy 




















cohort of 5-year 
survivors treated 
in 1995-1995 and 
diagnosed at age 
≤16 years in 














radiation dose to 
the tail, body and 
head of pancreas, 
and radiation 
doses to most of 
the other organs 
of the body and 


















The cumulative incidence of diabetes by age 
45 years was 6.6% (95% CI. 4.8-9.0%) among 
patients who had received radiation therapy 
and 2.3% (95% CI: 0.8-6.4%) among patients 
who had not received radiation therapy 
(p<0.001). Risk of diabetes increased strongly 
with radiation dose to the tail of the pancreas. 
No dose-response relationship was found for 
radiation to other parts of the pancreas. 
Compared with patients who did not receive 
radiotherapy, the relative risk of diabetes was 
11.5 (95% CI 3.9–34.0) in patients who 
received 10 Gy or more to the tail of the 
pancreas. 
















cohort of 5-year 
survivors 
diagnosed before 
20 years of age 
























































to estimate mean 
radiation doses to 
the heart and left 
ventricle). 
Heart failure The cumulative incidence of heart failure by 
age 30 years was 2.5% (95% CI: 2.1-2.9%) 
and by age 50 years it was 5.7% (95% CI: 5.0-
6.6%). The risk of heart failure increased with 
increasing volumes of the heart and left 
ventricle of  ≥30 Gy. The risk of heart failure 













cohort of 5-year 
survivors 
diagnosed before 
16 years of age 



















to the circle of 





Stroke Survivors receiving radiation therapy had a 
8.5-fold increased risk of a stroke (95% CI: 
6.3-11.0), where those not receiving radiation 
therapy had similar risk of stroke as the general 
population. For radiation dose of ≥ 40 Gy to 
the circle of the Willis, the risk of stroke was 
15.7 (95% CI: 4.9-50.2), and risk also 
increased with radiation doses to the heart and 
neck. At 45 years of age, the cumulative stroke 
incidence was 11.3% (95% CI: 7.1-17.7%) in 
survivors who received ≥10 Gy to the circle of 
the Willis, compared with 1% expected from 
general population data. 















1980 with acute 
leukaemia below 
the age of 18 
years, and being 










































Survivors had metabolic syndrome more often 
than comparisons (10.3% vs 4.5%, OR: 2.49, 
95% CI: 1.91-3.25). The cumulative incidence 
of metabolic syndrome at age 25 years was 
7.9% (95% CI: 6.0-10.3%) and 14.4% (95% 
CI: 11.2-18.4%) at age 30 years. Survivors 
receiving HSCT had highest prevalence of 
metabolic syndrome, especially those who also 
received total body irradiation before HSCT 



















the age of 18 
years and in 
complete 














































Post-HSCT cataract occurred among 41.7% of 
the patients. Cataract was more frequent after 
allogeneic than after autologous 
transplantation. 
The 15-year cumulative incidence was 70.9% 
for patients receiving total body irradiation and 
12.5% in the Busulfan group. Higher 
cumulative steroid dose was also a significant 



















































Survivors had an 11-fold increased risk of 
death (standardised mortality ratio (SMR): 
11.0, 95% CI: 10.7-12.0), corresponding to an 
AER of 48 (95% CI: 45-51). The most 
frequent causes of death were relapse of the 
initial cancer (56%), subsequent primary 
cancers (19%), and cardiovascular events 
(5.8%). The probability of long-term survival 
at 25, 35, and 45 years from diagnosis was 
91%, 87% and 81%, respectively. Mortality 
decreased by 60% for survivors treated most 
recently (1990-1999). 
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20 years of age 































































≥ 2b vs no 
ototoxicity as 
Münster class 
1 and 2a). 
Within the cohort, 54% of patients developed 
minor hearing loss, and 22% of patients 
developed clinically relevant hearing loss after 
cisplatin treatment. Higher cumulative dose of 
cisplatin (>450 vs ≤300 mg/m2) increased the 
risk of ototoxicity (OR: 2.4; 95% CI: 1.3–4.6). 
None of the ten assessed SNPs from ten 
different genes were significantly associated 
with ototoxicity risk. A meta-analysis of this 
PanCareLIFE study and four previous studies 
indicated a significant association between the 
ACYP2 rs1872328 variant and cisplatin 
ototoxicity risk (OR: 3.94, 95% CI: 1.04–
14.93), and between the SLC22A2 rs316019 
and cisplatin ototoxicity risk (OR: 1.46, 95% 
CI: 1.07-2.00). 
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AER; Absolute excess risk, ALL; Acute lymphoblastic leukaemia, AML; Acute myeloid leukaemia, CML; Chronic myeloid leukaemia, CTCAE; Common Terminology 
Criteria for Adverse Events, CNS; Central nervous system, GSI; Global severity index, HSCT; hematopoietic stem cell transplantation, HQoL; Health-related quality of life, 
 ICD; International classification of diseases, NCSI; National Cancer Survivorship Initiative, OR; Odds ratio, O/E; Observed/expected, RR; Risk ratio, SIR; Standardised 
incidence ratio, SMR; Standardised mortality ratio, SPN; Subsequent primary neoplasm 
**PanCareLIFE was an EU-funded consortium active from 2013-2018, with publications expected in the years to come. http://www.pancarelife.eu/ 
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Table 4: Summary of the largest and most comprehensive studies on mental late effects based on childhood cancer survivor cohorts in Europe and North 




















































































Subsets of survivors reported persistently 
elevated prevalence of depression (8.9%), 
anxiety (4.8%), and somatisation (7.2%). 
Increasing distress symptoms were predicted 
by survivor perception of worsening physical 
health over time (depression OR 3.3, anxiety 






























































Among survivors, 7.8% reported suicide 
ideation compared with 4.6% of controls (OR: 
1.79, 95% CI: 1.4-2.4). Poor physical health 
was significantly associated (OR 12.5, 95% CI 
8.0-19.5) with suicide ideation even after 
adjusting for cancer diagnosis and reported 
depression. 












cohort of 5-year 
cancer survivors 
aged ≥20 years at 
survey and 
diagnosed in 




































may have had 
surgery), 
chemotherapy 



















in the Global 
Severity 
Index (GSI). 
Survivors reported low levels of psychological 
distress on average, but increased distress for 
interpersonal sensitivity (16.5%), depression 
(13.4%), aggression (16.9%), and psychotic 
tendencies (15.6%) than the expected 10% in 
the norm population. Risk factors for 
psychological distress was female sex, being a 
single child, older age at study, and self-
reported late effects. Comparisons with 
psychotherapy patients indicated that 
















































Among survivors, 21.6% filled an 
antidepressant prescription during follow-up 
compared with 18.6% among population 
comparisons (OR: 1.21, 95% CI: 1.09-1.35), 
with increased risks observed for all individual 
types of antidepressants and for multiple 
antidepressants. Survivors diagnosed between 
ages 15 and 20 years had nearly twice the odds 
of an antidepressant prescription than those 
diagnosed before age 5 (OR: 1.89, 95% CI: 
1.04–3.45), whereas no large differences were 
seen for specific treatments. 
AER; Absolute excess risk, ALL; Acute lymphoblastic leukaemia, AML; Acute myeloid leukaemia, CML; Chronic myeloid leukaemia, CTCAE; Common Terminology 
Criteria for Adverse Events, CNS; Central nervous system, GSI; Global severity index, HSCT; hematopoietic stem cell transplantation, HQoL; Health-related quality of life, 
 ICD; International classification of diseases, NCSI; National Cancer Survivorship Initiative, OR; Odds ratio, O/E; Observed/expected, RR; Risk ratio, SIR; Standardised 
incidence ratio, SMR; Standardised mortality ratio, SPN; Subsequent primary neoplasm 
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